1018-00009 · Client 1018 · Strategy

royalty-rate-analysis-memo.docx DOCUMENT M&A / Corporate

166 / 176 ← → ✕

PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT

MEMORANDUM

Right-click to update Table of Contents

I. Executive Summary

The purpose of this memorandum is to analyze the legal framework governing the arm's-length royalty rate applicable to the intercompany license of legacy pharmaceutical intellectual property ("IP") from Penterra Pharmaceuticals Corp. ("PPC") to Penterra Biopharma International DAC ("PBI"), and to assess the defensibility of PPC's 4.5% royalty rate under Section 482 of the Internal Revenue Code of 1986, as amended ("IRC § 482"), and the Treasury Regulations promulgated thereunder, with particular emphasis on Treas. Reg. § 1.482-4.

PPC licenses certain pre-2012 legacy compounds — that is, compounds not covered by the qualified cost-sharing arrangement ("CSA") that became effective July 1, 2012 — to PBI at a royalty rate of 4.5% of net sales for exploitation in the non-Americas territory. The non-Americas territory encompasses all countries outside North America, Central America, South America, and the Caribbean. These legacy compounds are mature pharmaceutical products in the later stages of their product lifecycle, and their non-Americas net sales during the examination period under review reflect a consistent and pronounced decline:

Over the four-year examination period, non-Americas net sales of legacy compounds declined by approximately 23.4%, reflecting the natural erosion expected of mature pharmaceutical products facing generic competition, patent expiry, and formulary displacement.

The Internal Revenue Service ("IRS") is expected to challenge the 4.5% royalty rate. Early indications from Information Document Requests ("IDRs") and informal communications during the examination suggest that the IRS may rely on comparable uncontrolled transaction ("CUT") data to propose a significantly higher royalty rate in the range of 10% to 12%. This anticipated position appears to rest on the selection of comparable license agreements involving higher-value, growth-stage or blockbuster pharmaceutical compounds — transactions that are fundamentally distinguishable from PPC's legacy IP license on multiple comparability dimensions.

It is the conclusion of this memorandum that PPC's 4.5% royalty rate is well-supported under the CUT method when proper comparability adjustments are applied in accordance with the requirements of Treas. Reg. § 1.482-4(c)(2). The rate falls within — and near the median of — the interquartile range ("IQR") identified by the Whitmore Valuation Group's ("Whitmore") preliminary benchmarking analysis. Specifically, Whitmore's analysis of 14 comparable uncontrolled pharmaceutical license agreements yields an IQR of 3.1% to 6.8%, with a median of 4.4%. PPC's 4.5% royalty rate is virtually indistinguishable from the median and is comfortably situated within the arm's-length range as defined by Treas. Reg. § 1.482-1(e). PPC has strong legal and factual defenses against any proposed upward adjustment.

II. Factual Background

A. The Parties and Corporate Structure

Penterra Pharmaceuticals Corp. ("PPC"). PPC is a corporation organized under the laws of the State of Delaware and publicly traded on the Nasdaq Stock Market under the ticker symbol "PPCA." PPC is headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceuticals and biotechnology company focused on oncology, immunology, and rare-disease therapeutics. For its fiscal year ending December 31, 2020, PPC reported consolidated revenue of approximately $6.82 billion and pre-tax income of approximately $1.47 billion. PPC employed approximately 14,500 individuals globally as of December 31, 2020. PPC is the ultimate parent entity of the Penterra corporate group and serves as the U.S. tax reporting entity for the consolidated group.

Penterra Biopharma International DAC ("PBI"). PBI is a Designated Activity Company organized under the laws of Ireland, with its registered office at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI was incorporated on March 15, 2012, approximately three and a half months prior to the effective date of the CSA. PBI functions as the IP-holding company and principal for the non-Americas commercialization of the Penterra group's pharmaceutical products. For its fiscal year ending December 31, 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. PBI's headcount grew from 52 employees at its establishment in 2012 to 185 employees as of December 31, 2020, reflecting the build-out of substantive operational capabilities in Dublin over the relevant period.

Penterra Holdings Luxembourg S.à r.l. ("PHL"). PHL is a société à responsabilité limitée organized under the laws of the Grand Duchy of Luxembourg, with its registered office at 14, rue Aldringen, L-1118 Luxembourg. PHL is a 100% subsidiary of PPC and serves as an intermediate holding company. PHL is the 100% owner of PBI. PHL is treated as a disregarded entity for U.S. federal income tax purposes pursuant to Treas. Reg. § 301.7701-3. Accordingly, for U.S. federal tax purposes, PBI is treated as a direct subsidiary of PPC.

Ownership Chain. The relevant ownership chain is: PPC → PHL (disregarded entity) → PBI. Because PHL is disregarded, the controlled transaction at issue — the license of legacy IP from PPC to PBI — is treated as a direct transaction between PPC and PBI for purposes of IRC § 482 and the regulations thereunder.

B. The Legacy IP License Agreement

Separate and distinct from the CSA (which became effective July 1, 2012), PPC entered into a license agreement with PBI (the "Legacy License Agreement" or the "Legacy License") pursuant to which PPC licenses certain legacy compounds to PBI for exploitation outside the Americas. For purposes of the Legacy License, the "Americas" is defined to include North America (the United States, Canada, and Mexico), Central America, South America, and the Caribbean. All territories outside the Americas — including the European Economic Area, the United Kingdom, Switzerland, Japan, Australia, South Korea, and approximately 60 additional country markets — constitute the "non-Americas territory" or the "Licensed Territory."

The legacy compounds are those pharmaceutical products that were developed prior to 2012 — specifically, compounds whose development was substantially complete, or whose regulatory approvals had been obtained, before the CSA effective date of July 1, 2012. These compounds are not covered by the CSA. The CSA, by contrast, applies to compounds developed after its effective date and governs the cost-sharing of intangible development costs between PPC and PBI for those newer compounds. The Legacy License and the CSA are governed by separate agreements with distinct pricing terms, covering distinct sets of intangible property.

Under the Legacy License, PBI pays PPC a royalty of 4.5% of net sales attributable to the legacy compounds in the non-Americas territory. Net sales are defined consistently with PPC's public financial reporting methodology: gross sales less returns, rebates, chargebacks, distribution fees, and applicable government-mandated discounts.

These legacy compounds are mature products in the later stages of their product lifecycle. Non-Americas net sales have declined consistently from $814.6 million in 2017 to $624.1 million in 2020, a cumulative decline of approximately 23.4% over the four-year examination period. This decline reflects the expected erosion pattern for branded pharmaceutical products facing loss of patent protection, entry of generic competitors, formulary displacement by newer therapies, and general market maturation.

Under the terms of the Legacy License, PPC retains ownership of the underlying IP — including patents, trademarks, regulatory filings, and associated know-how — and PBI receives the right to commercialize the licensed compounds in the non-Americas territory. PBI does not acquire ownership of any of the underlying intangible property; it acquires only a license to exploit that property in its territory.

C. PBI's Functions, Assets, and Risks Relevant to the Legacy License

PBI is not a bare licensee or a passive recipient of IP rights. Since its incorporation in 2012, PBI has built substantial operational capabilities and performs a broad range of substantive functions in connection with the commercialization of licensed products — both legacy compounds and CSA-covered compounds — in the non-Americas territory. The following functional profile is relevant to the comparability analysis under Treas. Reg. § 1.482-4(c)(2):

Functions Performed. PBI performs regulatory affairs management, including the preparation, filing, and maintenance of marketing authorization applications, label updates, post-marketing surveillance reports, and periodic safety update reports with regulatory agencies across the Licensed Territory. PBI maintains a dedicated medical affairs team responsible for medical information inquiries, medical science liaison activities, and clinical evidence generation. PBI develops and executes commercial strategy — including product positioning, pricing strategy, key account management, and market access planning — independently across 68 distinct country markets. PBI manages supply-chain logistics, including demand forecasting, inventory management, and coordination of product distribution across its markets. PBI makes independent pricing decisions, which is a particularly significant functional attribute given the diversity of pricing environments in its territory, ranging from free-market pricing in certain jurisdictions to strict government price controls and reference pricing systems in others.

Assets Employed. As of December 31, 2020, PBI maintained 185 employees at its Dublin headquarters, occupying approximately 18,000 square feet of office space. PBI held 42 board of directors meetings during the 2017–2020 examination period, all of which took place in Dublin. PBI's board included both PPC-nominated directors and independent directors with relevant pharmaceutical industry experience. PBI maintained its principal banking relationship with Glenmore Bank Ireland plc and engaged Thornbury & Keogh (Ciarán Thornbury, lead partner) as its Irish tax advisors.

Risks Assumed. PBI bore market risk for the non-Americas territories, including the risk that products would fail to achieve or sustain anticipated sales volumes due to competitive dynamics, formulary exclusions, or regulatory actions. PBI bore pricing risk — the risk that government-imposed price reductions, reference pricing adjustments, or competitive pressures would reduce achievable net selling prices. PBI bore regulatory risk — the risk that regulatory agencies would impose labeling restrictions, require additional post-marketing studies, or take other actions that would adversely affect the commercial viability of licensed products. PBI bore demand risk — the risk that healthcare provider prescribing patterns or patient demand would shift away from PBI's products in favor of therapeutic alternatives.

Regulatory Expenditures. During the 2017–2020 examination period, PBI incurred approximately €47.2 million cumulatively in regulatory expenditures and submissions across the non-Americas territory. These expenditures included fees for regulatory filings, label variation applications, pharmacovigilance activities, and post-marketing commitment studies.

Contract Manufacturing. PBI managed the contract manufacturing of pharmaceutical products through Penterra Manufacturing Ireland Limited ("PMI"), a wholly owned subsidiary operating a manufacturing facility in Ringaskiddy, County Cork, Ireland. PMI employed approximately 620 individuals and was compensated on a cost-plus basis, receiving cost plus an 8% markup for manufacturing services. The manufacturing arrangement is tested separately under CPM and is not at issue in the royalty rate analysis.

Irish Tax Position. PBI claimed Ireland's Knowledge Development box ("KDB") rate of 6.25% (effective from FY 2016 forward) on qualifying income derived from qualifying patents. Income not qualifying for the KDB rate was subject to the standard Irish corporation tax trading rate of 12.5%.

D. Key Products Under the Legacy License

The legacy compounds licensed to PBI under the Legacy License are distinct from the newer products — including Veritaxol, Imvara, and Cerulon — that are primarily covered by the CSA. The legacy compounds were developed and approved prior to the CSA effective date and represent older-generation therapies in their respective indications. While the specific compound identities are detailed in the Legacy License Agreement (produced to the IRS in response to IDR No. 3), the following characteristics are relevant for purposes of the transfer pricing analysis:

The legacy compounds are in the mature or declining phase of their commercial lifecycle. Non-Americas net sales declined from $814.6 million in 2017 to $624.1 million in 2020. Several of the legacy compounds have experienced loss of regulatory exclusivity in key markets during or prior to the examination period, resulting in generic competition and corresponding price and volume erosion. The legacy compounds are not "Blockbuster" products in the traditional pharmaceutical industry sense; they are established, proven therapies with diminishing commercial value.

It is important to note that the same functional infrastructure at PBI — the same employees, office space, regulatory affairs team, commercial strategy team, and supply-chain management capabilities — supports both the CSA-covered products and the legacy-licensed products in the non-Americas territory. This shared infrastructure is relevant to the functional analysis because it demonstrates that PBI performs substantive value-adding functions irrespective of whether a given product is licensed under the Legacy License or developed under the CSA. The allocation of PBI's costs between CSA-covered and legacy-licensed activities is addressed in PPC's contemporaneous transfer pricing documentation.

The declining sales trajectory of the legacy products is a critical comparability factor in the CUT analysis. Comparable uncontrolled license agreements involving growth-stage or peak-stage pharmaceutical products would not be reliably comparable to the Legacy License without significant comparability adjustments to account for the difference in expected revenue trajectories, remaining useful life, and competitive positioning.

E. PPC's Transfer Pricing Documentation

PPC maintained contemporaneous transfer pricing documentation for each of the four tax years under examination (2017, 2018, 2019, and 2020), prepared in accordance with the requirements of IRC § 6662(e) and Treas. Reg. § 1.6662-6 for purposes of establishing penalty protection. The documentation was prepared by Crestfield & Associates LLP ("Crestfield"), with Susan Lam serving as the Transfer Pricing Partner and Martin Ogilvy serving as the Engagement Partner.

The contemporaneous documentation applied the CUT method as the best method for testing the arm's-length character of the 4.5% royalty rate under Treas. Reg. § 1.482-4. For each tax year, the documentation included: (i) a description of the controlled transaction and the parties; (ii) an analysis of the functions performed, assets employed, and risks assumed by PPC and PBI in connection with the Legacy License; (iii) a best method analysis selecting the CUT method; (iv) a search for comparable uncontrolled transactions; (v) a comparability analysis of identified CUT agreements; (vi) a computation of the arm's-length range; and (vii) a conclusion that the 4.5% royalty rate fell within the arm's-length range.

The documentation was prepared on a timely basis and was available on the date of the filing of the relevant tax returns. As discussed in Section VII below, this contemporaneous documentation provides important penalty protection for PPC's royalty rate position.

F. The IRS Examination

The IRS opened an examination of PPC's federal income tax returns for the 2017 through 2020 tax years on May 16, 2022, as communicated by IRS Letter 2205-A. The examination is being conducted by the IRS Large Business & International ("LB&I") Division, Northeast Transfer Pricing Practice. The Examination Team carries the identification number LB&I-NE-TP-2022-00641.

The IRS Examination Team comprises the following key personnel:

• Lead Revenue Agent: Patricia Dunleavy

• Supervisory Revenue Agent (Team Manager): Gerald Meskill

• IRS Economist: Dr. Alan Washburne

• IRS Chief Counsel Attorney-Advisor: Franklin Rosario

• Senior Counsel: Donna Hirabayashi

Calderwood & Harkness LLP ("C&H") was engaged by PPC on June 2, 2022, to represent PPC in the examination and any subsequent proceedings. On June 20, 2022, C&H retained Whitmore Valuation Group under a Kovel letter (reference 1018-00009-KV) to provide independent economic analyses in support of PPC's transfer pricing positions. The Kovel arrangement ensures that Whitmore's work product is protected by attorney-client privilege and the work product doctrine.

As of the date of this memorandum, the IRS has issued 47 Information Document Requests. Of particular relevance to the Legacy License royalty rate analysis, IDR No. 3 specifically requested the Legacy IP License Agreement itself, which was produced in full. IDR No. 25 requested comparable license agreements and CUT support underlying PPC's contemporaneous transfer pricing documentation. The response to IDR No. 25 is being coordinated with Whitmore and requires careful consideration of privilege and work product protections, as discussed in Section X below.

III. Applicable Legal Framework

A. IRC § 482 — General Authority

IRC § 482 provides the Commissioner of Internal Revenue with broad authority to distribute, apportion, or allocate gross income, deductions, credits, or allowances among two or more organizations, trades, or businesses that are "owned or controlled directly or indirectly by the same interests" if the Commissioner determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income of any of such organizations, trades, or businesses. The statute provides, in relevant part:

In any case of two or more organizations, trades, or businesses (whether or not incorporated, whether or not organized in the United States, and whether or not affiliated) owned or controlled directly or indirectly by the same interests, the Secretary may distribute, apportion, or allocate gross income, deductions, credits, or allowances between or among such organizations, trades, or businesses, if he determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income of any of such organizations, trades, or businesses.

The fundamental principle underlying IRC § 482 and its implementing regulations is the arm's-length standard. As articulated in Treas. Reg. § 1.482-1(b)(1), the purpose of section 482 is to ensure that taxpayers clearly reflect income attributable to controlled transactions and to prevent the avoidance of taxes with respect to such transactions. The arm's-length standard requires that controlled transactions produce results consistent with the results that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances. Treas. Reg. § 1.482-1(b)(1) states:

The purpose of section 482 is to ensure that taxpayers clearly reflect income attributable to controlled transactions, and to prevent the avoidance of taxes with respect to such transactions. Section 482 places a controlled taxpayer on a tax parity with an uncontrolled taxpayer by determining the true taxable income of the controlled taxpayer.

Treas. Reg. § 1.482-1(d) further elaborates on the arm's-length standard, providing that whether a controlled transaction produces an arm's-length result is generally determined by comparing the results of the controlled transaction with the results of uncontrolled transactions that are comparable to the controlled transaction under the comparability standards set forth in the regulations. This comparison forms the backbone of the transfer pricing analysis at issue in this memorandum.

It is well established that the Commissioner bears the initial burden of demonstrating that the taxpayer's reported income does not clearly reflect income within the meaning of IRC § 482, but that once the Commissioner establishes a prima facie case, the burden shifts to the taxpayer to demonstrate that the Commissioner's allocation is arbitrary, capricious, or unreasonable. See Sundstrand Corp. v. Commissioner, 96 T.C. 226, 353 (1991); Crowne Albany Industries v. Commissioner, 84 T.C. 996 (1985), aff'd in part, rev'd in part, 856 F.2d 855 (7th Cir. 1988). In practice, both parties in a transfer pricing dispute must present affirmative evidence supporting their respective proposed arm's-length results.

B. Treas. Reg. § 1.482-4 — Methods to Determine Taxable Income in Connection with a Transfer of Intangible Property

1. Overview of Available Methods. Treas. Reg. § 1.482-4(a) specifies the methods available for determining the arm's-length consideration for controlled transfers of intangible property. The regulations define "intangible property" broadly to include patents, inventions, formulae, processes, designs, patterns, know-how, copyrights, literary or artistic compositions, trademarks, trade names, franchises, licenses, contracts, and similar items that have substantial value independent of the services of any individual. The licensed legacy pharmaceutical compounds — encompassing patents, regulatory approvals, clinical data, manufacturing know-how, and associated trademarks — constitute intangible property within the meaning of the regulations.

The methods specified under Treas. Reg. § 1.482-4(a) for testing whether a controlled transfer of intangible property satisfies the arm's-length standard include:

(i) The comparable uncontrolled transaction ("CUT") method under Treas. Reg. § 1.482-4(c);

(ii) The comparable profits method ("CPM") under Treas. Reg. § 1.482-5;

(iii) The profit split method under Treas. Reg. § 1.482-6; and

(iv) Unspecified methods under Treas. Reg. § 1.482-4(d).

The regulations establish a hierarchy of reliability, with the CUT method generally considered the most reliable method when sufficiently comparable uncontrolled transactions exist. This preference reflects the regulatory premise that the most direct evidence of an arm's-length result is the price actually charged in comparable transactions between uncontrolled parties. However, as discussed below in connection with the best method rule, the CUT method's reliability depends critically on the degree of comparability between the controlled and uncontrolled transactions and the quality of any comparability adjustments applied.

2. The Comparable Uncontrolled Transaction (CUT) Method — § 1.482-4(c). The CUT method evaluates whether the amount charged in a controlled transfer of intangible property is arm's length by reference to the amount charged in a comparable uncontrolled transaction. Treas. Reg. § 1.482-4(c)(1) provides the general rule that the CUT method evaluates the arm's-length charge for a controlled transfer of intangible property by reference to the amount charged in a comparable uncontrolled transaction.

Two types of CUTs may be identified and applied:

Internal CUTs. An internal CUT is a transaction between the controlled taxpayer (or a member of its controlled group) and an uncontrolled party involving the same or substantially similar intangible property under comparable circumstances. Internal CUTs are generally considered more reliable than external CUTs because they involve the same intangible property and one of the same parties, thereby reducing the number of comparability differences that must be evaluated and adjusted.

External CUTs. An external CUT is a transaction between two uncontrolled parties involving comparable intangible property under comparable circumstances. External CUTs are more commonly available than internal CUTs but require more extensive comparability analysis because they involve different intangible property and different parties.

In the context of pharmaceutical IP licensing, the CUT method compares the royalty rate charged in the controlled license (here, the 4.5% rate under the Legacy License) to royalty rates observed in comparable uncontrolled license agreements involving pharmaceutical or biopharmaceutical intangible property. The key analytical challenge is ensuring that the uncontrolled license agreements are sufficiently comparable to the controlled transaction, or that reliable comparability adjustments can be made to account for material differences.

3. Comparability Factors Under § 1.482-4(c)(2). The regulations provide both general and specific comparability factors that must be considered in evaluating whether an uncontrolled transaction is comparable to the controlled transaction under review.

General Comparability Factors. Treas. Reg. § 1.482-1(d)(3) sets forth general comparability factors applicable to all methods, including: (i) functions performed by the parties; (ii) contractual terms of the transaction; (iii) risks assumed by each party; (iv) economic conditions, including market conditions, at the time of the transaction; and (v) the nature and characteristics of the property or services transferred. These general factors provide the overarching framework for comparability analysis and must be considered in conjunction with the method-specific factors.

Specific Comparability Factors for Intangible Property. Treas. Reg. § 1.482-4(c)(2)(iii) identifies additional comparability factors that are particularly relevant when evaluating the comparability of intangible property transactions:

(A) Whether the intangible property is used in connection with the same or similar products or processes;

(B) The stage of development of the intangible (for example, whether it has been commercially proven or is still in an experimental or clinical-development stage);

(C) The rights conferred in the transaction, including whether the grant is exclusive or non-exclusive, the geographic scope of the rights, and the field of use;

(D) The duration and terms of the license or other arrangement;

(E) The economic conditions existing at the time of the transaction, including the competitive environment, the regulatory environment, and the general economic conditions in the relevant markets;

(F) The risks assumed by each party, including market risk, regulatory risk, and obsolescence risk;

(G) Whether the intangible is expected to generate income over a limited or indefinite period; and

(H) The uniqueness and value of the intangible, including the expected profit-generating capacity and the absence or presence of competing alternatives.

Each of these factors bears directly on the comparability analysis for PPC's Legacy License. Their application to the facts of PPC's case is discussed in detail below:

Product/process similarity (Factor A). Comparable uncontrolled transactions should involve pharmaceutical or biopharmaceutical intangible property — ideally, license agreements for approved, commercialized pharmaceutical compounds rather than platform technology licenses, research tool licenses, or early-stage R&D collaborations. Moreover, comparables involving mature or legacy compounds are more relevant than those involving blockbuster or pipeline assets, because the profit-generating characteristics of mature and declining products are fundamentally different from those of products at peak or growth stages. Whitmore's search criteria appropriately limited the comparables set to pharmaceutical and biopharmaceutical IP licensing transactions.

Stage of development (Factor B). PPC's legacy compounds are commercially proven but declining. They have been on the market for a number of years, have established safety and efficacy profiles, and are well past the stage of regulatory uncertainty. However, their commercial value is diminishing as a result of generic competition and therapeutic displacement. Comparables involving peak-stage or growth-stage IP — where the intangible is expected to generate increasing or stable revenues — would require substantial downward adjustment to reflect the declining trajectory of PPC's legacy compounds. A failure to make such adjustments would systematically overstate the arm's-length royalty rate.

Rights conferred (Factor C). PBI received exclusive commercialization rights for the non-Americas territory under the Legacy License. This is a significant but geographically limited grant. The exclusivity provides PBI with the sole right to exploit the licensed IP in the Licensed Territory, which carries value but also imposes on PBI the full burden of commercialization — including the costs and risks of regulatory compliance, market access, and competitive positioning in approximately 68 country markets with varying regulatory and pricing environments. Comparables must be evaluated for the geographic scope of the rights conferred, the exclusivity or non-exclusivity of the grant, and any field-of-use restrictions.

Duration (Factor D). The Legacy License does not have a single fixed expiration date tied to the patent life of any individual compound. Rather, the effective duration of the license depends on the remaining patent and data exclusivity periods of each licensed compound in each country within the Licensed Territory, as well as the continued commercial viability of the products. As a practical matter, the diminishing commercial value of the legacy compounds and the expiration of key patent protections during and after the examination period mean that the effective remaining life of the license is limited — a factor that supports a lower royalty rate. Comparables with longer effective durations or involving IP with significant remaining patent life may require downward adjustment.

Risks (Factor F). As detailed in Section II.C above, PBI bears substantial risks in connection with the Legacy License, including market risk, pricing risk, regulatory risk, and demand risk. In an arm's-length transaction, a licensee bearing greater risks would demand a lower royalty rate (and correspondingly retain a larger share of profits) to compensate for the risk it assumes. Comparables in which the licensor retains significant risks — or in which the licensee bears fewer risks — would need to be adjusted to reflect the risk allocation under the Legacy License.

Uniqueness and value (Factor H). The legacy compounds, while proprietary and protected by intellectual property rights, are not uniquely valuable "crown jewel" assets in the manner of a novel first-in-class or breakthrough therapy. They are established products in the decline phase, facing generic competition and therapeutic obsolescence. The reduced uniqueness and diminishing value of these intangibles support a lower royalty rate compared to what an arm's-length licensor could command for high-value, differentiated pharmaceutical IP with significant remaining market exclusivity.

C. The Best Method Rule — Treas. Reg. § 1.482-1(c)

Treas. Reg. § 1.482-1(c) establishes the "best method rule," which provides that the arm's-length result of a controlled transaction must be determined under the method that, under the facts and circumstances, provides the most reliable measure of an arm's-length result. There is no strict hierarchy among the specified methods; however, the regulations and case law recognize that the CUT method is generally the most reliable method when sufficiently comparable uncontrolled transactions can be identified because it provides the most direct evidence of an arm's-length price.

The reliability of a method is evaluated based on two primary factors:

(i) The degree of comparability between the controlled transaction and any uncontrolled comparables, taking into account all relevant comparability factors; and

(ii) The quality of the data and assumptions used in applying the method.

The CUT method is considered the most reliable when truly comparable uncontrolled transactions exist — that is, when the uncontrolled transactions involve sufficiently similar intangible property, similar rights and obligations, similar risk allocations, and similar economic conditions. However, where imperfect comparability exists — as is almost invariably the case in practice — the reliability of the CUT method depends on the ability to make reliable comparability adjustments. If reliable adjustments cannot be made to account for material differences between the controlled and uncontrolled transactions, other methods (such as CPM or the profit split method) may provide a more reliable measure of the arm's-length result.

Application to PPC. PPC's position is that the CUT method is the best method for testing the arm's-length character of the 4.5% royalty rate because: (a) a sufficient set of comparable uncontrolled pharmaceutical license agreements exists — Whitmore Valuation Group has identified 14 such agreements meeting the screening criteria; and (b) the comparability differences between the controlled and uncontrolled transactions can be identified and reliably adjusted. The availability of 14 comparable agreements — each involving pharmaceutical IP licensing between unrelated parties, with identifiable terms and royalty rates — provides a robust data set for the CUT analysis. While no uncontrolled comparable will be a perfect match for PPC's Legacy License, the adjustments necessary to account for differences in product lifecycle stage, geographic scope, risk allocation, and other factors can be reliably quantified or directionally assessed. Accordingly, the CUT method provides the most direct and reliable measure of the arm's-length royalty rate for the Legacy License.

The alternative methods — CPM and the profit split method — are less reliable for this purpose. CPM tests a taxpayer's overall profitability against the profitability of comparable companies but does not directly test the royalty rate itself; it is better suited to testing routine transactions or the profitability of the "tested party" in a transaction where the intangible cannot be directly priced. The profit split method requires a reliable allocation of combined profits between the parties but introduces its own complexities and assumptions regarding profit allocation keys. Given the availability of directly comparable royalty data, the CUT method is the most reliable approach.

D. The Arm's-Length Range — Treas. Reg. § 1.482-1(e)

Treas. Reg. § 1.482-1(e) provides the rules governing the arm's-length range. Where the application of the best method produces two or more comparable uncontrolled transactions, the results of those transactions may define a range of arm's-length results. The regulations provide that the arm's-length range is ordinarily defined as the interquartile range — that is, the range from the 25th percentile to the 75th percentile — of the results derived from the comparable transactions.

The regulatory rules provide two critical consequences:

First, if the controlled transaction falls within the arm's-length range (the IQR), no adjustment under IRC § 482 is warranted. The taxpayer's pricing is treated as arm's-length. See Treas. Reg. § 1.482-1(e)(1).

Second, if the controlled transaction falls outside the arm's-length range, the IRS may adjust the taxpayer's result to the median of the arm's-length range. See Treas. Reg. § 1.482-1(e)(3).

Application to PPC. Whitmore's preliminary analysis of 14 comparable uncontrolled pharmaceutical license agreements yields the following interquartile range:

• 25th percentile (lower bound of IQR): 3.1%

• Median: 4.4%

• 75th percentile (upper bound of IQR): 6.8%

PPC's 4.5% royalty rate falls squarely within the interquartile range of 3.1% to 6.8%. Moreover, PPC's rate of 4.5% is virtually indistinguishable from the median of 4.4% — a difference of only 10 basis points. Under the regulatory framework, because PPC's royalty rate falls within the IQR, no adjustment is warranted under IRC § 482. Even if the IRS were to establish that an adjustment were appropriate (which PPC contests), the adjustment point under the regulations would be the median of 4.4% — which would actually result in a downward adjustment of 10 basis points, not an upward adjustment. This statistical positioning provides PPC with a powerful defense.

E. Periodic Adjustments — Treas. Reg. § 1.482-4(f)(2)

The Tax Reform Act of 1986 amended IRC § 482 to add the requirement that, in the case of a transfer or license of intangible property, the consideration must be "commensurate with the income attributable to the intangible." This "commensurate with income" ("CWI") standard authorizes the IRS to make periodic adjustments to the consideration charged for intangible property transfers if the actual profitability of the intangible differs significantly from what was reasonably anticipated at the time the transfer or license was entered into.

Treas. Reg. § 1.482-4(f)(2) implements the periodic adjustment authority. The regulation provides that the IRS may make adjustments in taxable years subsequent to the initial transfer or license if the actual profits or cost savings attributable to the intangible differ significantly from the level of profits or cost savings that were foreseeable at the time of the transaction. The purpose of the periodic adjustment mechanism is to address situations in which the value of an intangible turns out to be significantly greater (or lesser) than anticipated — in other words, to address windfalls or disappointments that were not foreseeable.

Application to PPC. The IRS may invoke the CWI standard to argue that the 4.5% royalty rate should be adjusted upward based on PBI's overall profitability during the examination period. However, the periodic adjustment mechanism is fundamentally inapplicable to PPC's legacy IP license for two reasons:

First, the legacy compound profitability is declining, not outperforming expectations. Non-Americas net sales of legacy compounds dropped from $814.6 million in 2017 to $624.1 million in 2020 — a decline of approximately 23.4%. The periodic adjustment mechanism under § 1.482-4(f)(2) is designed for situations of significant outperformance — where the intangible turns out to be far more valuable than anticipated at the time of the license. Here, the opposite has occurred: the legacy compounds are generating less revenue over time, consistent with the natural decline of mature pharmaceutical products. An upward periodic adjustment in the face of declining performance would be internally inconsistent and contrary to the regulatory purpose of the CWI standard.

Second, even if PBI's overall profitability is robust during the examination period, that profitability reflects not only the value of the legacy IP but also (and increasingly) the value of CSA-covered products (Veritaxol, Imvara, Cerulon) and, critically, PBI's own contributions through its substantive functions, assets, and risk-bearing. Attributing PBI's total profitability to the legacy IP alone conflates the return on PBI's own contributions with the return on PPC's licensed IP and is inconsistent with the arm's-length standard.

Treas. Reg. § 1.482-4(f)(2)(ii) also provides certain exceptions to periodic adjustments, including where the taxpayer establishes that the controlled transaction was entered into at arm's-length terms based on the information reasonably available at the time and that the deviation from projected results is due to extraordinary events or circumstances that were not reasonably foreseeable. PPC's declining legacy compound sales fall squarely within the category of natural product lifecycle decline and do not trigger the conditions for an upward periodic adjustment.

F. Aggregation vs. Disaggregation of Transactions — § 1.482-1(f)(2)

An important threshold issue in the transfer pricing analysis is whether the Legacy License royalty arrangement should be analyzed on a standalone basis or aggregated with the CSA. The IRS may attempt to view PBI's overall profit level holistically — considering both the profitability of CSA-covered products and legacy-licensed products — in an effort to argue that PBI is over-compensated or that the royalty rate should be adjusted to reflect the overall economics of the PPC-PBI relationship.

Treas. Reg. § 1.482-1(f)(2)(i) addresses the aggregation of transactions. The regulation generally provides that transactions may be aggregated for purposes of the arm's-length analysis where they are so interrelated that the evaluation of one transaction in isolation would not yield a reliable arm's-length result. However, the regulation also provides for disaggregation where transactions are economically distinct and are subject to separate pricing terms.

PPC's Position. The Legacy License and the CSA are separate transactions covering distinct sets of intangible property — pre-2012 legacy compounds versus post-2012 CSA-developed IP — and should be analyzed independently under separate transfer pricing methods. The key grounds for disaggregation are as follows:

(i) The Legacy License and the CSA involve different intangible property. The legacy compounds were developed before 2012 and are wholly owned by PPC; the CSA-developed IP was created after July 1, 2012, and is subject to shared cost-sharing ownership under the CSA.

(ii) The two arrangements have different pricing mechanisms. The Legacy License applies a royalty rate of 4.5% of net sales; the CSA applies a cost-sharing ratio for sharing intangible development costs and a platform contribution transaction ("PCT") payment for pre-existing intangibles contributed to the CSA.

(iii) The economic profiles of the two arrangements are fundamentally different. The legacy compounds are mature and declining, while the CSA-covered products (Veritaxol, Imvara, Cerulon) are in growth phases with expanding revenue trajectories.

(iv) The separate pricing terms for each arrangement were established independently and reflect the distinct economic characteristics of the underlying IP.

Aggregating the Legacy License with the CSA for analytical purposes would distort the comparability analysis by blending the economics of declining legacy products with the economics of growing CSA-covered products. Such aggregation would undermine the reliability of any transfer pricing method applied to the combined transactions.

If the IRS attempts aggregation, PPC should rely on Treas. Reg. § 1.482-1(f)(2)(i), which supports disaggregation where the transactions are economically distinct and have separate pricing terms, as well as on the fundamental principle that the arm's-length standard requires testing each controlled transaction against comparable uncontrolled transactions with similar economic characteristics.

IV. Analysis of PPC's 4.5% Royalty Rate Under the CUT Method

A. Selection and Application of the CUT Method as Best Method

As discussed in Section III.C above, the CUT method is selected as the best method for testing the arm's-length character of the 4.5% royalty rate under the Legacy License. The rationale for this selection rests on two pillars: the availability of sufficiently comparable uncontrolled pharmaceutical license agreements, and the ability to make reliable comparability adjustments to account for differences between the controlled and uncontrolled transactions.

Rationale for Selecting CUT Over Other Methods. The CUT method is preferred over the CPM, the profit split method, and unspecified methods for the following reasons:

CPM (Treas. Reg. § 1.482-5): The CPM tests the overall operating profitability of the "tested party" against the profitability of comparable companies. While CPM can provide a reliable arm's-length result in many transfer pricing contexts — particularly for testing routine distribution or service functions — it is a less direct method for testing a specific royalty rate. CPM does not directly compare royalty rates; it compares overall profit levels. Moreover, CPM requires the identification of comparable companies performing similar functions with similar risk profiles, which presents its own comparability challenges. Because directly comparable royalty rate data is available, the CUT method provides a more reliable measure of the arm's-length royalty rate.

Profit Split Method (Treas. Reg. § 1.482-6): The profit split method allocates combined profits between the controlled parties based on their relative contributions to the generation of those profits. While this method can be appropriate in cases involving highly integrated operations and unique, valuable intangibles, it introduces substantial complexity regarding the identification and valuation of each party's contributions and the selection of appropriate profit-allocation keys. The profit split method is generally applied in situations where both parties make unique and valuable contributions to the transaction, making one-sided methods unreliable. Here, the Legacy License involves a relatively straightforward IP licensing arrangement for mature compounds, and the CUT method provides a more direct and reliable pricing benchmark.

Unspecified Methods (Treas. Reg. § 1.482-4(d)): Unspecified methods may be applied where none of the specified methods produce a reliable result. Given the availability of 14 comparable uncontrolled transactions and the reliability of the CUT analysis, resort to unspecified methods is neither necessary nor appropriate.

Availability of Comparable Data. The Whitmore Valuation Group, working under C&H direction and protected by the Kovel arrangement, identified 14 comparable uncontrolled pharmaceutical license agreements suitable for application of the CUT method. These agreements were identified through a comprehensive search of publicly available sources, including SEC filings (10-K, 10-Q, and 8-K filings), pharmaceutical industry databases (including the Vireo Health IT and Sundial Health IT databases), litigation disclosures, and published industry surveys. Each of the 14 agreements involves the licensing of pharmaceutical or biopharmaceutical intangible property between unrelated parties and satisfies the screening criteria described below.

Internal CUTs. C&H and Whitmore evaluated whether PPC maintains any third-party license agreements that could serve as internal CUTs — that is, licenses of the same or substantially similar legacy compounds to unrelated third parties. PPC's third-party licensing activity is limited. PPC has entered into certain distribution agreements with third-party distributors in specific country markets, but these arrangements are structured as distribution agreements with limited IP licensing components rather than as IP royalty licenses comparable to the Legacy License. Additionally, certain third-party license-back arrangements exist in connection with historical acquisition agreements, but these involve different compounds under different terms and are not directly comparable to the Legacy License. Accordingly, while PPC's internal licensing history was considered, the primary CUT data set consists of 14 external CUTs.

B. Comparability Analysis for the 14 CUT Agreements

Screening Criteria. Whitmore applied the following screening criteria to identify the 14 comparable uncontrolled pharmaceutical license agreements:

• Industry: The licensing agreements involve pharmaceutical or biopharmaceutical intangible property. Licenses involving medical devices, diagnostic tools, agricultural chemicals, or other non-pharmaceutical IP were excluded as insufficiently comparable to the Legacy License.

• Type of IP: The licensed IP consists of approved, commercialized pharmaceutical compounds — not early-stage R&D compounds, platform technology licenses, research tool licenses, or compound library access agreements. This criterion ensures that the comparables involve IP at a similar stage of commercial realization as PPC's legacy compounds.

• Rights conferred: The comparables involve exclusive territorial licenses, typically non-U.S. or specific regional grants (e.g., European Economic Area, Asia-Pacific, or defined multi-country regions). Non-exclusive licenses, worldwide licenses, and U.S.-only licenses were excluded or adjusted as appropriate.

• Stage of development: The comparables involve mature or post-launch compounds — products that have been commercially launched and are in the later stages of their commercial lifecycle. This criterion is critical to ensuring comparability with PPC's legacy compounds, which are in a declining phase. Agreements involving pre-launch or growth-stage compounds were excluded or subjected to comparability adjustments.

• Term: The comparables involve multi-year license agreements — not one-time lump-sum transfers, option agreements, or short-term research collaborations.

• Data availability: The comparable agreements are publicly available or disclosed in SEC filings, litigation records, or searchable databases, with sufficient detail regarding royalty rates, licensed products, territorial scope, and key terms to permit meaningful comparability analysis.

Comparability Adjustments Required and Made. No set of comparable uncontrolled transactions will perfectly match the controlled transaction in all respects. Accordingly, Whitmore identified the following categories of comparability differences and applied or will apply adjustments as appropriate:

Geographic Scope Adjustments. Some of the 14 comparable agreements cover different territory definitions than the non-Americas territory under the Legacy License. For example, certain comparables grant rights to a specific region (e.g., Europe only) while others grant broader non-U.S. rights. Adjustments were made to account for differences in territory size, market characteristics, and the number and diversity of country markets covered. In general, broader territorial grants covering more diverse markets with varying regulatory and pricing environments tend to be associated with moderately lower royalty rates, reflecting the greater operational complexity and risk borne by the licensee.

Product Lifecycle Adjustments. While the screening criteria targeted mature or post-launch compounds, certain comparables involve products at somewhat different stages of their lifecycle than PPC's legacy compounds. Products in the early post-launch or peak-sales phase generate higher expected revenues and therefore command higher royalty rates than products in the declining phase. Whitmore applied adjustments to normalize for lifecycle-stage differences, generally adjusting downward the royalty rates of comparables involving products with longer expected remaining commercial lives or more favorable competitive positions.

Exclusivity Adjustments. All 14 comparables involve exclusive territorial licenses, consistent with the Legacy License. However, the scope of exclusivity varies (e.g., sole and exclusive vs. exclusive with reserved rights). To the extent any comparables deviate from the exclusivity terms of the Legacy License, adjustments were considered.

Risk Allocation Adjustments. The allocation of risks between licensor and licensee varies across the comparable agreements. In some comparables, the licensee bears full market, regulatory, and pricing risk (consistent with the Legacy License), while in others, certain risks are shared with or retained by the licensor (e.g., through co-promotion arrangements, milestone-based pricing, or regulatory support obligations). Adjustments were made to account for these differences, recognizing that greater risk-bearing by the licensee supports a lower royalty rate.

Volume/Scale Adjustments. The legacy compounds generate significant annual net sales in the non-Americas territory ($624.1 million to $814.6 million during the examination period), which may differ from the sales volumes of the products covered by the comparable agreements. Volume-based adjustments were considered to the extent that royalty rates in the comparables were influenced by differences in sales scale.

Results. After application of the screening criteria and comparability adjustments, Whitmore's preliminary analysis of the 14 comparable uncontrolled pharmaceutical license agreements yields the following arm's-length range:

PPC's 4.5% royalty rate falls within the interquartile range (3.1% to 6.8%) and is essentially at the median of 4.4%. Under Treas. Reg. § 1.482-1(e), a controlled transaction that falls within the arm's-length range does not warrant an adjustment. PPC's royalty rate is not merely within the range — it is at the central tendency of the distribution. This provides PPC with a strong evidentiary position.

C. Specific Comparability Factors Favoring PPC's Rate

1. Declining Product Lifecycle. The most significant comparability factor favoring PPC's 4.5% royalty rate is the declining product lifecycle of the legacy compounds. Non-Americas net sales dropped from $814.6 million in 2017 to $624.1 million in 2020, a decline of approximately 23.4% over the four-year examination period. This decline trajectory is consistent with the natural lifecycle of branded pharmaceutical products facing loss of patent exclusivity, generic competition, and therapeutic displacement by newer agents.

The declining revenue trajectory directly reduces the present value of the IP to the licensee. From the licensee's perspective, the economic value of a license depends on the expected future cash flows attributable to the licensed IP. When those expected cash flows are declining — and when the licensee has no realistic expectation of revenue recovery absent significant new investment or reformulation — the license is inherently less valuable than a license of peak-stage or growth-stage IP. A rational arm's-length licensee in PBI's position would demand a lower royalty rate to reflect the diminishing value of the IP and the increasing risk that revenues will continue to decline. Conversely, a rational arm's-length licensor in PPC's position would accept a lower rate rather than risk the licensee declining to renew or maintain the license altogether.

Comparables involving blockbuster or high-growth pharmaceutical IP — where the expected revenue trajectory is upward and the product faces minimal near-term competitive threats — would significantly overstate the appropriate arm's-length royalty rate for PPC's declining legacy compounds. Any CUT analysis that fails to adjust for lifecycle-stage differences between the comparables and PPC's legacy compounds would produce unreliable results.

2. PBI's Substantive Functions and Risk-Bearing. A second critical factor favoring PPC's rate is PBI's status as a substantive, risk-bearing licensee — not a passive recipient of IP rights. The arm's-length standard recognizes that, in an uncontrolled transaction, a licensee that performs significant value-adding functions and bears substantial risks will negotiate a lower royalty rate than a licensee that merely distributes a finished product with minimal operational involvement.

PBI performs significant DEMPE functions — Development, Enhancement, Maintenance, Protection, and Exploitation — in connection with the commercialization of licensed products in the non-Americas territory:

• Development and Enhancement: While PPC owns the underlying IP, PBI contributes to the ongoing development and enhancement of the licensed products' commercial potential through label expansion submissions, formulation adaptations for local markets, and medical affairs-driven clinical evidence generation in non-Americas territories.

• Maintenance and Protection: PBI incurred €47.2 million cumulatively in regulatory expenditures during the examination period, maintaining regulatory approvals, managing pharmacovigilance obligations, and defending the intellectual property rights of the licensed products in the Licensed Territory.

• Exploitation: PBI independently develops and executes commercial strategy across 68 country markets, makes independent pricing decisions, manages key account relationships with healthcare systems and payers, and bears the full risk of commercial success or failure in each market.

PBI's economic substance is robust and well-documented. PBI maintained 185 employees as of December 31, 2020, occupying approximately 18,000 square feet of dedicated office space in Dublin. PBI's board of directors held 42 meetings during the 2017–2020 examination period — all in Dublin — reflecting active governance and independent decision-making. PBI managed its own treasury function through Glenmore Bank Ireland plc and engaged independent Irish tax advisors (Thornbury & Keogh) and auditors.

PBI's substantive functions and risk-bearing justify attributing a larger share of the profits from the Legacy License to PBI's own activities, and correspondingly a lower royalty rate to PPC's IP. An arm's-length royalty rate must reflect the relative contributions of both parties: PPC contributes the underlying IP (which is declining in value), and PBI contributes the operational infrastructure, market expertise, regulatory compliance, and risk-bearing necessary to exploit that IP across 68 diverse country markets. A 4.5% royalty rate appropriately reflects this allocation.

3. Exclusivity and Geographic Scope. The Legacy License grants PBI exclusive rights to commercialize the licensed compounds in the non-Americas territory. While exclusivity is a valuable right — and generally supports a higher royalty rate compared to a non-exclusive license — the geographic scope and market characteristics of the Licensed Territory introduce countervailing factors that moderate the value of the exclusivity grant.

The non-Americas territory encompasses a highly fragmented set of markets with significant regulatory, pricing, and reimbursement complexity. The territory includes markets with strict government price controls (e.g., France, Germany, Japan, South Korea), reference pricing systems that link prices across countries, mandatory rebate programs, and highly variable reimbursement processes. These market characteristics reduce the net value of the licensed IP to the licensee compared to, for example, a license for the U.S. market — where pricing is generally more favorable for branded pharmaceuticals and regulatory requirements, while stringent, are administered by a single agency (the FDA).

Additionally, the non-Americas territory requires the licensee to navigate approximately 68 distinct regulatory environments, each with its own marketing authorization requirements, post-marketing surveillance obligations, and pharmacovigilance standards. The operational burden and cost of maintaining compliance across these diverse jurisdictions are borne by PBI, not PPC, and represent a significant functional contribution that supports a lower royalty rate.

4. Absence of Sub-licensing Rights. Under the terms of the Legacy License, PBI does not have the right to sub-license the licensed IP to third parties without PPC's prior written consent. This restriction limits PBI's ability to exploit the licensed IP through third-party arrangements and reduces the flexibility and value of the license compared to a license that includes unrestricted sub-licensing rights. In the comparable uncontrolled transactions, licenses that include broader sub-licensing rights are generally associated with higher royalty rates, reflecting the greater flexibility

PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT
MEMORANDUM
Right-click to update Table of Contents
I. Executive Summary
The purpose of this memorandum is to analyze the legal framework governing the arm's-length royalty rate applicable to the intercompany license of legacy pharmaceutical intellectual property ("IP") from Penterra Pharmaceuticals Corp. ("PPC") to Penterra Biopharma International DAC ("PBI"), and to assess the defensibility of PPC's 4.5% royalty rate under Section 482 of the Internal Revenue Code of 1986, as amended ("IRC § 482"), and the Treasury Regulations promulgated thereunder, with particular emphasis on Treas. Reg. § 1.482-4.
PPC licenses certain pre-2012 legacy compounds — that is, compounds not covered by the qualified cost-sharing arrangement ("CSA") that became effective July 1, 2012 — to PBI at a royalty rate of 4.5% of net sales for exploitation in the non-Americas territory. The non-Americas territory encompasses all countries outside North America, Central America, South America, and the Caribbean. These legacy compounds are mature pharmaceutical products in the later stages of their product lifecycle, and their non-Americas net sales during the examination period under review reflect a consistent and pronounced decline:
Over the four-year examination period, non-Americas net sales of legacy compounds declined by approximately 23.4%, reflecting the natural erosion expected of mature pharmaceutical products facing generic competition, patent expiry, and formulary displacement.
The Internal Revenue Service ("IRS") is expected to challenge the 4.5% royalty rate. Early indications from Information Document Requests ("IDRs") and informal communications during the examination suggest that the IRS may rely on comparable uncontrolled transaction ("CUT") data to propose a significantly higher royalty rate in the range of 10% to 12%. This anticipated position appears to rest on the selection of comparable license agreements involving higher-value, growth-stage or blockbuster pharmaceutical compounds — transactions that are fundamentally distinguishable from PPC's legacy IP license on multiple comparability dimensions.
It is the conclusion of this memorandum that PPC's 4.5% royalty rate is well-supported under the CUT method when proper comparability adjustments are applied in accordance with the requirements of Treas. Reg. § 1.482-4(c)(2). The rate falls within — and near the median of — the interquartile range ("IQR") identified by the Whitmore Valuation Group's ("Whitmore") preliminary benchmarking analysis. Specifically, Whitmore's analysis of 14 comparable uncontrolled pharmaceutical license agreements yields an IQR of 3.1% to 6.8%, with a median of 4.4%. PPC's 4.5% royalty rate is virtually indistinguishable from the median and is comfortably situated within the arm's-length range as defined by Treas. Reg. § 1.482-1(e). PPC has strong legal and factual defenses against any proposed upward adjustment.
II. Factual Background
A. The Parties and Corporate Structure
Penterra Pharmaceuticals Corp. ("PPC"). PPC is a corporation organized under the laws of the State of Delaware and publicly traded on the Nasdaq Stock Market under the ticker symbol "PPCA." PPC is headquartered at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceuticals and biotechnology company focused on oncology, immunology, and rare-disease therapeutics. For its fiscal year ending December 31, 2020, PPC reported consolidated revenue of approximately $6.82 billion and pre-tax income of approximately $1.47 billion. PPC employed approximately 14,500 individuals globally as of December 31, 2020. PPC is the ultimate parent entity of the Penterra corporate group and serves as the U.S. tax reporting entity for the consolidated group.
Penterra Biopharma International DAC ("PBI"). PBI is a Designated Activity Company organized under the laws of Ireland, with its registered office at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI was incorporated on March 15, 2012, approximately three and a half months prior to the effective date of the CSA. PBI functions as the IP-holding company and principal for the non-Americas commercialization of the Penterra group's pharmaceutical products. For its fiscal year ending December 31, 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. PBI's headcount grew from 52 employees at its establishment in 2012 to 185 employees as of December 31, 2020, reflecting the build-out of substantive operational capabilities in Dublin over the relevant period.
Penterra Holdings Luxembourg S.à r.l. ("PHL"). PHL is a société à responsabilité limitée organized under the laws of the Grand Duchy of Luxembourg, with its registered office at 14, rue Aldringen, L-1118 Luxembourg. PHL is a 100% subsidiary of PPC and serves as an intermediate holding company. PHL is the 100% owner of PBI. PHL is treated as a disregarded entity for U.S. federal income tax purposes pursuant to Treas. Reg. § 301.7701-3. Accordingly, for U.S. federal tax purposes, PBI is treated as a direct subsidiary of PPC.
Ownership Chain. The relevant ownership chain is: PPC → PHL (disregarded entity) → PBI. Because PHL is disregarded, the controlled transaction at issue — the license of legacy IP from PPC to PBI — is treated as a direct transaction between PPC and PBI for purposes of IRC § 482 and the regulations thereunder.
B. The Legacy IP License Agreement
Separate and distinct from the CSA (which became effective July 1, 2012), PPC entered into a license agreement with PBI (the "Legacy License Agreement" or the "Legacy License") pursuant to which PPC licenses certain legacy compounds to PBI for exploitation outside the Americas. For purposes of the Legacy License, the "Americas" is defined to include North America (the United States, Canada, and Mexico), Central America, South America, and the Caribbean. All territories outside the Americas — including the European Economic Area, the United Kingdom, Switzerland, Japan, Australia, South Korea, and approximately 60 additional country markets — constitute the "non-Americas territory" or the "Licensed Territory."
The legacy compounds are those pharmaceutical products that were developed prior to 2012 — specifically, compounds whose development was substantially complete, or whose regulatory approvals had been obtained, before the CSA effective date of July 1, 2012. These compounds are not covered by the CSA. The CSA, by contrast, applies to compounds developed after its effective date and governs the cost-sharing of intangible development costs between PPC and PBI for those newer compounds. The Legacy License and the CSA are governed by separate agreements with distinct pricing terms, covering distinct sets of intangible property.
Under the Legacy License, PBI pays PPC a royalty of 4.5% of net sales attributable to the legacy compounds in the non-Americas territory. Net sales are defined consistently with PPC's public financial reporting methodology: gross sales less returns, rebates, chargebacks, distribution fees, and applicable government-mandated discounts.
These legacy compounds are mature products in the later stages of their product lifecycle. Non-Americas net sales have declined consistently from $814.6 million in 2017 to $624.1 million in 2020, a cumulative decline of approximately 23.4% over the four-year examination period. This decline reflects the expected erosion pattern for branded pharmaceutical products facing loss of patent protection, entry of generic competitors, formulary displacement by newer therapies, and general market maturation.
Under the terms of the Legacy License, PPC retains ownership of the underlying IP — including patents, trademarks, regulatory filings, and associated know-how — and PBI receives the right to commercialize the licensed compounds in the non-Americas territory. PBI does not acquire ownership of any of the underlying intangible property; it acquires only a license to exploit that property in its territory.
C. PBI's Functions, Assets, and Risks Relevant to the Legacy License
PBI is not a bare licensee or a passive recipient of IP rights. Since its incorporation in 2012, PBI has built substantial operational capabilities and performs a broad range of substantive functions in connection with the commercialization of licensed products — both legacy compounds and CSA-covered compounds — in the non-Americas territory. The following functional profile is relevant to the comparability analysis under Treas. Reg. § 1.482-4(c)(2):
Functions Performed. PBI performs regulatory affairs management, including the preparation, filing, and maintenance of marketing authorization applications, label updates, post-marketing surveillance reports, and periodic safety update reports with regulatory agencies across the Licensed Territory. PBI maintains a dedicated medical affairs team responsible for medical information inquiries, medical science liaison activities, and clinical evidence generation. PBI develops and executes commercial strategy — including product positioning, pricing strategy, key account management, and market access planning — independently across 68 distinct country markets. PBI manages supply-chain logistics, including demand forecasting, inventory management, and coordination of product distribution across its markets. PBI makes independent pricing decisions, which is a particularly significant functional attribute given the diversity of pricing environments in its territory, ranging from free-market pricing in certain jurisdictions to strict government price controls and reference pricing systems in others.
Assets Employed. As of December 31, 2020, PBI maintained 185 employees at its Dublin headquarters, occupying approximately 18,000 square feet of office space. PBI held 42 board of directors meetings during the 2017–2020 examination period, all of which took place in Dublin. PBI's board included both PPC-nominated directors and independent directors with relevant pharmaceutical industry experience. PBI maintained its principal banking relationship with Glenmore Bank Ireland plc and engaged Thornbury & Keogh (Ciarán Thornbury, lead partner) as its Irish tax advisors.
Risks Assumed. PBI bore market risk for the non-Americas territories, including the risk that products would fail to achieve or sustain anticipated sales volumes due to competitive dynamics, formulary exclusions, or regulatory actions. PBI bore pricing risk — the risk that government-imposed price reductions, reference pricing adjustments, or competitive pressures would reduce achievable net selling prices. PBI bore regulatory risk — the risk that regulatory agencies would impose labeling restrictions, require additional post-marketing studies, or take other actions that would adversely affect the commercial viability of licensed products. PBI bore demand risk — the risk that healthcare provider prescribing patterns or patient demand would shift away from PBI's products in favor of therapeutic alternatives.
Regulatory Expenditures. During the 2017–2020 examination period, PBI incurred approximately €47.2 million cumulatively in regulatory expenditures and submissions across the non-Americas territory. These expenditures included fees for regulatory filings, label variation applications, pharmacovigilance activities, and post-marketing commitment studies.
Contract Manufacturing. PBI managed the contract manufacturing of pharmaceutical products through Penterra Manufacturing Ireland Limited ("PMI"), a wholly owned subsidiary operating a manufacturing facility in Ringaskiddy, County Cork, Ireland. PMI employed approximately 620 individuals and was compensated on a cost-plus basis, receiving cost plus an 8% markup for manufacturing services. The manufacturing arrangement is tested separately under CPM and is not at issue in the royalty rate analysis.
Irish Tax Position. PBI claimed Ireland's Knowledge Development box ("KDB") rate of 6.25% (effective from FY 2016 forward) on qualifying income derived from qualifying patents. Income not qualifying for the KDB rate was subject to the standard Irish corporation tax trading rate of 12.5%.
D. Key Products Under the Legacy License
The legacy compounds licensed to PBI under the Legacy License are distinct from the newer products — including Veritaxol, Imvara, and Cerulon — that are primarily covered by the CSA. The legacy compounds were developed and approved prior to the CSA effective date and represent older-generation therapies in their respective indications. While the specific compound identities are detailed in the Legacy License Agreement (produced to the IRS in response to IDR No. 3), the following characteristics are relevant for purposes of the transfer pricing analysis:
The legacy compounds are in the mature or declining phase of their commercial lifecycle. Non-Americas net sales declined from $814.6 million in 2017 to $624.1 million in 2020. Several of the legacy compounds have experienced loss of regulatory exclusivity in key markets during or prior to the examination period, resulting in generic competition and corresponding price and volume erosion. The legacy compounds are not "Blockbuster" products in the traditional pharmaceutical industry sense; they are established, proven therapies with diminishing commercial value.
It is important to note that the same functional infrastructure at PBI — the same employees, office space, regulatory affairs team, commercial strategy team, and supply-chain management capabilities — supports both the CSA-covered products and the legacy-licensed products in the non-Americas territory. This shared infrastructure is relevant to the functional analysis because it demonstrates that PBI performs substantive value-adding functions irrespective of whether a given product is licensed under the Legacy License or developed under the CSA. The allocation of PBI's costs between CSA-covered and legacy-licensed activities is addressed in PPC's contemporaneous transfer pricing documentation.
The declining sales trajectory of the legacy products is a critical comparability factor in the CUT analysis. Comparable uncontrolled license agreements involving growth-stage or peak-stage pharmaceutical products would not be reliably comparable to the Legacy License without significant comparability adjustments to account for the difference in expected revenue trajectories, remaining useful life, and competitive positioning.
E. PPC's Transfer Pricing Documentation
PPC maintained contemporaneous transfer pricing documentation for each of the four tax years under examination (2017, 2018, 2019, and 2020), prepared in accordance with the requirements of IRC § 6662(e) and Treas. Reg. § 1.6662-6 for purposes of establishing penalty protection. The documentation was prepared by Crestfield & Associates LLP ("Crestfield"), with Susan Lam serving as the Transfer Pricing Partner and Martin Ogilvy serving as the Engagement Partner.
The contemporaneous documentation applied the CUT method as the best method for testing the arm's-length character of the 4.5% royalty rate under Treas. Reg. § 1.482-4. For each tax year, the documentation included: (i) a description of the controlled transaction and the parties; (ii) an analysis of the functions performed, assets employed, and risks assumed by PPC and PBI in connection with the Legacy License; (iii) a best method analysis selecting the CUT method; (iv) a search for comparable uncontrolled transactions; (v) a comparability analysis of identified CUT agreements; (vi) a computation of the arm's-length range; and (vii) a conclusion that the 4.5% royalty rate fell within the arm's-length range.
The documentation was prepared on a timely basis and was available on the date of the filing of the relevant tax returns. As discussed in Section VII below, this contemporaneous documentation provides important penalty protection for PPC's royalty rate position.
F. The IRS Examination
The IRS opened an examination of PPC's federal income tax returns for the 2017 through 2020 tax years on May 16, 2022, as communicated by IRS Letter 2205-A. The examination is being conducted by the IRS Large Business & International ("LB&I") Division, Northeast Transfer Pricing Practice. The Examination Team carries the identification number LB&I-NE-TP-2022-00641.
The IRS Examination Team comprises the following key personnel:
• Lead Revenue Agent: Patricia Dunleavy
• Supervisory Revenue Agent (Team Manager): Gerald Meskill
• IRS Economist: Dr. Alan Washburne
• IRS Chief Counsel Attorney-Advisor: Franklin Rosario
• Senior Counsel: Donna Hirabayashi
Calderwood & Harkness LLP ("C&H") was engaged by PPC on June 2, 2022, to represent PPC in the examination and any subsequent proceedings. On June 20, 2022, C&H retained Whitmore Valuation Group under a Kovel letter (reference 1018-00009-KV) to provide independent economic analyses in support of PPC's transfer pricing positions. The Kovel arrangement ensures that Whitmore's work product is protected by attorney-client privilege and the work product doctrine.
As of the date of this memorandum, the IRS has issued 47 Information Document Requests. Of particular relevance to the Legacy License royalty rate analysis, IDR No. 3 specifically requested the Legacy IP License Agreement itself, which was produced in full. IDR No. 25 requested comparable license agreements and CUT support underlying PPC's contemporaneous transfer pricing documentation. The response to IDR No. 25 is being coordinated with Whitmore and requires careful consideration of privilege and work product protections, as discussed in Section X below.
III. Applicable Legal Framework
A. IRC § 482 — General Authority
IRC § 482 provides the Commissioner of Internal Revenue with broad authority to distribute, apportion, or allocate gross income, deductions, credits, or allowances among two or more organizations, trades, or businesses that are "owned or controlled directly or indirectly by the same interests" if the Commissioner determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income of any of such organizations, trades, or businesses. The statute provides, in relevant part:
In any case of two or more organizations, trades, or businesses (whether or not incorporated, whether or not organized in the United States, and whether or not affiliated) owned or controlled directly or indirectly by the same interests, the Secretary may distribute, apportion, or allocate gross income, deductions, credits, or allowances between or among such organizations, trades, or businesses, if he determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income of any of such organizations, trades, or businesses.
The fundamental principle underlying IRC § 482 and its implementing regulations is the arm's-length standard. As articulated in Treas. Reg. § 1.482-1(b)(1), the purpose of section 482 is to ensure that taxpayers clearly reflect income attributable to controlled transactions and to prevent the avoidance of taxes with respect to such transactions. The arm's-length standard requires that controlled transactions produce results consistent with the results that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances. Treas. Reg. § 1.482-1(b)(1) states:
The purpose of section 482 is to ensure that taxpayers clearly reflect income attributable to controlled transactions, and to prevent the avoidance of taxes with respect to such transactions. Section 482 places a controlled taxpayer on a tax parity with an uncontrolled taxpayer by determining the true taxable income of the controlled taxpayer.
Treas. Reg. § 1.482-1(d) further elaborates on the arm's-length standard, providing that whether a controlled transaction produces an arm's-length result is generally determined by comparing the results of the controlled transaction with the results of uncontrolled transactions that are comparable to the controlled transaction under the comparability standards set forth in the regulations. This comparison forms the backbone of the transfer pricing analysis at issue in this memorandum.
It is well established that the Commissioner bears the initial burden of demonstrating that the taxpayer's reported income does not clearly reflect income within the meaning of IRC § 482, but that once the Commissioner establishes a prima facie case, the burden shifts to the taxpayer to demonstrate that the Commissioner's allocation is arbitrary, capricious, or unreasonable. See Sundstrand Corp. v. Commissioner, 96 T.C. 226, 353 (1991); Crowne Albany Industries v. Commissioner, 84 T.C. 996 (1985), aff'd in part, rev'd in part, 856 F.2d 855 (7th Cir. 1988). In practice, both parties in a transfer pricing dispute must present affirmative evidence supporting their respective proposed arm's-length results.
B. Treas. Reg. § 1.482-4 — Methods to Determine Taxable Income in Connection with a Transfer of Intangible Property
1. Overview of Available Methods. Treas. Reg. § 1.482-4(a) specifies the methods available for determining the arm's-length consideration for controlled transfers of intangible property. The regulations define "intangible property" broadly to include patents, inventions, formulae, processes, designs, patterns, know-how, copyrights, literary or artistic compositions, trademarks, trade names, franchises, licenses, contracts, and similar items that have substantial value independent of the services of any individual. The licensed legacy pharmaceutical compounds — encompassing patents, regulatory approvals, clinical data, manufacturing know-how, and associated trademarks — constitute intangible property within the meaning of the regulations.
The methods specified under Treas. Reg. § 1.482-4(a) for testing whether a controlled transfer of intangible property satisfies the arm's-length standard include:
(i) The comparable uncontrolled transaction ("CUT") method under Treas. Reg. § 1.482-4(c);
(ii) The comparable profits method ("CPM") under Treas. Reg. § 1.482-5;
(iii) The profit split method under Treas. Reg. § 1.482-6; and
(iv) Unspecified methods under Treas. Reg. § 1.482-4(d).
The regulations establish a hierarchy of reliability, with the CUT method generally considered the most reliable method when sufficiently comparable uncontrolled transactions exist. This preference reflects the regulatory premise that the most direct evidence of an arm's-length result is the price actually charged in comparable transactions between uncontrolled parties. However, as discussed below in connection with the best method rule, the CUT method's reliability depends critically on the degree of comparability between the controlled and uncontrolled transactions and the quality of any comparability adjustments applied.
2. The Comparable Uncontrolled Transaction (CUT) Method — § 1.482-4(c). The CUT method evaluates whether the amount charged in a controlled transfer of intangible property is arm's length by reference to the amount charged in a comparable uncontrolled transaction. Treas. Reg. § 1.482-4(c)(1) provides the general rule that the CUT method evaluates the arm's-length charge for a controlled transfer of intangible property by reference to the amount charged in a comparable uncontrolled transaction.
Two types of CUTs may be identified and applied:
Internal CUTs. An internal CUT is a transaction between the controlled taxpayer (or a member of its controlled group) and an uncontrolled party involving the same or substantially similar intangible property under comparable circumstances. Internal CUTs are generally considered more reliable than external CUTs because they involve the same intangible property and one of the same parties, thereby reducing the number of comparability differences that must be evaluated and adjusted.
External CUTs. An external CUT is a transaction between two uncontrolled parties involving comparable intangible property under comparable circumstances. External CUTs are more commonly available than internal CUTs but require more extensive comparability analysis because they involve different intangible property and different parties.
In the context of pharmaceutical IP licensing, the CUT method compares the royalty rate charged in the controlled license (here, the 4.5% rate under the Legacy License) to royalty rates observed in comparable uncontrolled license agreements involving pharmaceutical or biopharmaceutical intangible property. The key analytical challenge is ensuring that the uncontrolled license agreements are sufficiently comparable to the controlled transaction, or that reliable comparability adjustments can be made to account for material differences.
3. Comparability Factors Under § 1.482-4(c)(2). The regulations provide both general and specific comparability factors that must be considered in evaluating whether an uncontrolled transaction is comparable to the controlled transaction under review.
General Comparability Factors. Treas. Reg. § 1.482-1(d)(3) sets forth general comparability factors applicable to all methods, including: (i) functions performed by the parties; (ii) contractual terms of the transaction; (iii) risks assumed by each party; (iv) economic conditions, including market conditions, at the time of the transaction; and (v) the nature and characteristics of the property or services transferred. These general factors provide the overarching framework for comparability analysis and must be considered in conjunction with the method-specific factors.
Specific Comparability Factors for Intangible Property. Treas. Reg. § 1.482-4(c)(2)(iii) identifies additional comparability factors that are particularly relevant when evaluating the comparability of intangible property transactions:
(A) Whether the intangible property is used in connection with the same or similar products or processes;
(B) The stage of development of the intangible (for example, whether it has been commercially proven or is still in an experimental or clinical-development stage);
(C) The rights conferred in the transaction, including whether the grant is exclusive or non-exclusive, the geographic scope of the rights, and the field of use;
(D) The duration and terms of the license or other arrangement;
(E) The economic conditions existing at the time of the transaction, including the competitive environment, the regulatory environment, and the general economic conditions in the relevant markets;
(F) The risks assumed by each party, including market risk, regulatory risk, and obsolescence risk;
(G) Whether the intangible is expected to generate income over a limited or indefinite period; and
(H) The uniqueness and value of the intangible, including the expected profit-generating capacity and the absence or presence of competing alternatives.
Each of these factors bears directly on the comparability analysis for PPC's Legacy License. Their application to the facts of PPC's case is discussed in detail below:
Product/process similarity (Factor A). Comparable uncontrolled transactions should involve pharmaceutical or biopharmaceutical intangible property — ideally, license agreements for approved, commercialized pharmaceutical compounds rather than platform technology licenses, research tool licenses, or early-stage R&D collaborations. Moreover, comparables involving mature or legacy compounds are more relevant than those involving blockbuster or pipeline assets, because the profit-generating characteristics of mature and declining products are fundamentally different from those of products at peak or growth stages. Whitmore's search criteria appropriately limited the comparables set to pharmaceutical and biopharmaceutical IP licensing transactions.
Stage of development (Factor B). PPC's legacy compounds are commercially proven but declining. They have been on the market for a number of years, have established safety and efficacy profiles, and are well past the stage of regulatory uncertainty. However, their commercial value is diminishing as a result of generic competition and therapeutic displacement. Comparables involving peak-stage or growth-stage IP — where the intangible is expected to generate increasing or stable revenues — would require substantial downward adjustment to reflect the declining trajectory of PPC's legacy compounds. A failure to make such adjustments would systematically overstate the arm's-length royalty rate.
Rights conferred (Factor C). PBI received exclusive commercialization rights for the non-Americas territory under the Legacy License. This is a significant but geographically limited grant. The exclusivity provides PBI with the sole right to exploit the licensed IP in the Licensed Territory, which carries value but also imposes on PBI the full burden of commercialization — including the costs and risks of regulatory compliance, market access, and competitive positioning in approximately 68 country markets with varying regulatory and pricing environments. Comparables must be evaluated for the geographic scope of the rights conferred, the exclusivity or non-exclusivity of the grant, and any field-of-use restrictions.
Duration (Factor D). The Legacy License does not have a single fixed expiration date tied to the patent life of any individual compound. Rather, the effective duration of the license depends on the remaining patent and data exclusivity periods of each licensed compound in each country within the Licensed Territory, as well as the continued commercial viability of the products. As a practical matter, the diminishing commercial value of the legacy compounds and the expiration of key patent protections during and after the examination period mean that the effective remaining life of the license is limited — a factor that supports a lower royalty rate. Comparables with longer effective durations or involving IP with significant remaining patent life may require downward adjustment.
Risks (Factor F). As detailed in Section II.C above, PBI bears substantial risks in connection with the Legacy License, including market risk, pricing risk, regulatory risk, and demand risk. In an arm's-length transaction, a licensee bearing greater risks would demand a lower royalty rate (and correspondingly retain a larger share of profits) to compensate for the risk it assumes. Comparables in which the licensor retains significant risks — or in which the licensee bears fewer risks — would need to be adjusted to reflect the risk allocation under the Legacy License.
Uniqueness and value (Factor H). The legacy compounds, while proprietary and protected by intellectual property rights, are not uniquely valuable "crown jewel" assets in the manner of a novel first-in-class or breakthrough therapy. They are established products in the decline phase, facing generic competition and therapeutic obsolescence. The reduced uniqueness and diminishing value of these intangibles support a lower royalty rate compared to what an arm's-length licensor could command for high-value, differentiated pharmaceutical IP with significant remaining market exclusivity.
C. The Best Method Rule — Treas. Reg. § 1.482-1(c)
Treas. Reg. § 1.482-1(c) establishes the "best method rule," which provides that the arm's-length result of a controlled transaction must be determined under the method that, under the facts and circumstances, provides the most reliable measure of an arm's-length result. There is no strict hierarchy among the specified methods; however, the regulations and case law recognize that the CUT method is generally the most reliable method when sufficiently comparable uncontrolled transactions can be identified because it provides the most direct evidence of an arm's-length price.
The reliability of a method is evaluated based on two primary factors:
(i) The degree of comparability between the controlled transaction and any uncontrolled comparables, taking into account all relevant comparability factors; and
(ii) The quality of the data and assumptions used in applying the method.
The CUT method is considered the most reliable when truly comparable uncontrolled transactions exist — that is, when the uncontrolled transactions involve sufficiently similar intangible property, similar rights and obligations, similar risk allocations, and similar economic conditions. However, where imperfect comparability exists — as is almost invariably the case in practice — the reliability of the CUT method depends on the ability to make reliable comparability adjustments. If reliable adjustments cannot be made to account for material differences between the controlled and uncontrolled transactions, other methods (such as CPM or the profit split method) may provide a more reliable measure of the arm's-length result.
Application to PPC. PPC's position is that the CUT method is the best method for testing the arm's-length character of the 4.5% royalty rate because: (a) a sufficient set of comparable uncontrolled pharmaceutical license agreements exists — Whitmore Valuation Group has identified 14 such agreements meeting the screening criteria; and (b) the comparability differences between the controlled and uncontrolled transactions can be identified and reliably adjusted. The availability of 14 comparable agreements — each involving pharmaceutical IP licensing between unrelated parties, with identifiable terms and royalty rates — provides a robust data set for the CUT analysis. While no uncontrolled comparable will be a perfect match for PPC's Legacy License, the adjustments necessary to account for differences in product lifecycle stage, geographic scope, risk allocation, and other factors can be reliably quantified or directionally assessed. Accordingly, the CUT method provides the most direct and reliable measure of the arm's-length royalty rate for the Legacy License.
The alternative methods — CPM and the profit split method — are less reliable for this purpose. CPM tests a taxpayer's overall profitability against the profitability of comparable companies but does not directly test the royalty rate itself; it is better suited to testing routine transactions or the profitability of the "tested party" in a transaction where the intangible cannot be directly priced. The profit split method requires a reliable allocation of combined profits between the parties but introduces its own complexities and assumptions regarding profit allocation keys. Given the availability of directly comparable royalty data, the CUT method is the most reliable approach.
D. The Arm's-Length Range — Treas. Reg. § 1.482-1(e)
Treas. Reg. § 1.482-1(e) provides the rules governing the arm's-length range. Where the application of the best method produces two or more comparable uncontrolled transactions, the results of those transactions may define a range of arm's-length results. The regulations provide that the arm's-length range is ordinarily defined as the interquartile range — that is, the range from the 25th percentile to the 75th percentile — of the results derived from the comparable transactions.
The regulatory rules provide two critical consequences:
First, if the controlled transaction falls within the arm's-length range (the IQR), no adjustment under IRC § 482 is warranted. The taxpayer's pricing is treated as arm's-length. See Treas. Reg. § 1.482-1(e)(1).
Second, if the controlled transaction falls outside the arm's-length range, the IRS may adjust the taxpayer's result to the median of the arm's-length range. See Treas. Reg. § 1.482-1(e)(3).
Application to PPC. Whitmore's preliminary analysis of 14 comparable uncontrolled pharmaceutical license agreements yields the following interquartile range:
• 25th percentile (lower bound of IQR): 3.1%
• Median: 4.4%
• 75th percentile (upper bound of IQR): 6.8%
PPC's 4.5% royalty rate falls squarely within the interquartile range of 3.1% to 6.8%. Moreover, PPC's rate of 4.5% is virtually indistinguishable from the median of 4.4% — a difference of only 10 basis points. Under the regulatory framework, because PPC's royalty rate falls within the IQR, no adjustment is warranted under IRC § 482. Even if the IRS were to establish that an adjustment were appropriate (which PPC contests), the adjustment point under the regulations would be the median of 4.4% — which would actually result in a downward adjustment of 10 basis points, not an upward adjustment. This statistical positioning provides PPC with a powerful defense.
E. Periodic Adjustments — Treas. Reg. § 1.482-4(f)(2)
The Tax Reform Act of 1986 amended IRC § 482 to add the requirement that, in the case of a transfer or license of intangible property, the consideration must be "commensurate with the income attributable to the intangible." This "commensurate with income" ("CWI") standard authorizes the IRS to make periodic adjustments to the consideration charged for intangible property transfers if the actual profitability of the intangible differs significantly from what was reasonably anticipated at the time the transfer or license was entered into.
Treas. Reg. § 1.482-4(f)(2) implements the periodic adjustment authority. The regulation provides that the IRS may make adjustments in taxable years subsequent to the initial transfer or license if the actual profits or cost savings attributable to the intangible differ significantly from the level of profits or cost savings that were foreseeable at the time of the transaction. The purpose of the periodic adjustment mechanism is to address situations in which the value of an intangible turns out to be significantly greater (or lesser) than anticipated — in other words, to address windfalls or disappointments that were not foreseeable.
Application to PPC. The IRS may invoke the CWI standard to argue that the 4.5% royalty rate should be adjusted upward based on PBI's overall profitability during the examination period. However, the periodic adjustment mechanism is fundamentally inapplicable to PPC's legacy IP license for two reasons:
First, the legacy compound profitability is declining, not outperforming expectations. Non-Americas net sales of legacy compounds dropped from $814.6 million in 2017 to $624.1 million in 2020 — a decline of approximately 23.4%. The periodic adjustment mechanism under § 1.482-4(f)(2) is designed for situations of significant outperformance — where the intangible turns out to be far more valuable than anticipated at the time of the license. Here, the opposite has occurred: the legacy compounds are generating less revenue over time, consistent with the natural decline of mature pharmaceutical products. An upward periodic adjustment in the face of declining performance would be internally inconsistent and contrary to the regulatory purpose of the CWI standard.
Second, even if PBI's overall profitability is robust during the examination period, that profitability reflects not only the value of the legacy IP but also (and increasingly) the value of CSA-covered products (Veritaxol, Imvara, Cerulon) and, critically, PBI's own contributions through its substantive functions, assets, and risk-bearing. Attributing PBI's total profitability to the legacy IP alone conflates the return on PBI's own contributions with the return on PPC's licensed IP and is inconsistent with the arm's-length standard.
Treas. Reg. § 1.482-4(f)(2)(ii) also provides certain exceptions to periodic adjustments, including where the taxpayer establishes that the controlled transaction was entered into at arm's-length terms based on the information reasonably available at the time and that the deviation from projected results is due to extraordinary events or circumstances that were not reasonably foreseeable. PPC's declining legacy compound sales fall squarely within the category of natural product lifecycle decline and do not trigger the conditions for an upward periodic adjustment.
F. Aggregation vs. Disaggregation of Transactions — § 1.482-1(f)(2)
An important threshold issue in the transfer pricing analysis is whether the Legacy License royalty arrangement should be analyzed on a standalone basis or aggregated with the CSA. The IRS may attempt to view PBI's overall profit level holistically — considering both the profitability of CSA-covered products and legacy-licensed products — in an effort to argue that PBI is over-compensated or that the royalty rate should be adjusted to reflect the overall economics of the PPC-PBI relationship.
Treas. Reg. § 1.482-1(f)(2)(i) addresses the aggregation of transactions. The regulation generally provides that transactions may be aggregated for purposes of the arm's-length analysis where they are so interrelated that the evaluation of one transaction in isolation would not yield a reliable arm's-length result. However, the regulation also provides for disaggregation where transactions are economically distinct and are subject to separate pricing terms.
PPC's Position. The Legacy License and the CSA are separate transactions covering distinct sets of intangible property — pre-2012 legacy compounds versus post-2012 CSA-developed IP — and should be analyzed independently under separate transfer pricing methods. The key grounds for disaggregation are as follows:
(i) The Legacy License and the CSA involve different intangible property. The legacy compounds were developed before 2012 and are wholly owned by PPC; the CSA-developed IP was created after July 1, 2012, and is subject to shared cost-sharing ownership under the CSA.
(ii) The two arrangements have different pricing mechanisms. The Legacy License applies a royalty rate of 4.5% of net sales; the CSA applies a cost-sharing ratio for sharing intangible development costs and a platform contribution transaction ("PCT") payment for pre-existing intangibles contributed to the CSA.
(iii) The economic profiles of the two arrangements are fundamentally different. The legacy compounds are mature and declining, while the CSA-covered products (Veritaxol, Imvara, Cerulon) are in growth phases with expanding revenue trajectories.
(iv) The separate pricing terms for each arrangement were established independently and reflect the distinct economic characteristics of the underlying IP.
Aggregating the Legacy License with the CSA for analytical purposes would distort the comparability analysis by blending the economics of declining legacy products with the economics of growing CSA-covered products. Such aggregation would undermine the reliability of any transfer pricing method applied to the combined transactions.
If the IRS attempts aggregation, PPC should rely on Treas. Reg. § 1.482-1(f)(2)(i), which supports disaggregation where the transactions are economically distinct and have separate pricing terms, as well as on the fundamental principle that the arm's-length standard requires testing each controlled transaction against comparable uncontrolled transactions with similar economic characteristics.
IV. Analysis of PPC's 4.5% Royalty Rate Under the CUT Method
A. Selection and Application of the CUT Method as Best Method
As discussed in Section III.C above, the CUT method is selected as the best method for testing the arm's-length character of the 4.5% royalty rate under the Legacy License. The rationale for this selection rests on two pillars: the availability of sufficiently comparable uncontrolled pharmaceutical license agreements, and the ability to make reliable comparability adjustments to account for differences between the controlled and uncontrolled transactions.
Rationale for Selecting CUT Over Other Methods. The CUT method is preferred over the CPM, the profit split method, and unspecified methods for the following reasons:
CPM (Treas. Reg. § 1.482-5): The CPM tests the overall operating profitability of the "tested party" against the profitability of comparable companies. While CPM can provide a reliable arm's-length result in many transfer pricing contexts — particularly for testing routine distribution or service functions — it is a less direct method for testing a specific royalty rate. CPM does not directly compare royalty rates; it compares overall profit levels. Moreover, CPM requires the identification of comparable companies performing similar functions with similar risk profiles, which presents its own comparability challenges. Because directly comparable royalty rate data is available, the CUT method provides a more reliable measure of the arm's-length royalty rate.
Profit Split Method (Treas. Reg. § 1.482-6): The profit split method allocates combined profits between the controlled parties based on their relative contributions to the generation of those profits. While this method can be appropriate in cases involving highly integrated operations and unique, valuable intangibles, it introduces substantial complexity regarding the identification and valuation of each party's contributions and the selection of appropriate profit-allocation keys. The profit split method is generally applied in situations where both parties make unique and valuable contributions to the transaction, making one-sided methods unreliable. Here, the Legacy License involves a relatively straightforward IP licensing arrangement for mature compounds, and the CUT method provides a more direct and reliable pricing benchmark.
Unspecified Methods (Treas. Reg. § 1.482-4(d)): Unspecified methods may be applied where none of the specified methods produce a reliable result. Given the availability of 14 comparable uncontrolled transactions and the reliability of the CUT analysis, resort to unspecified methods is neither necessary nor appropriate.
Availability of Comparable Data. The Whitmore Valuation Group, working under C&H direction and protected by the Kovel arrangement, identified 14 comparable uncontrolled pharmaceutical license agreements suitable for application of the CUT method. These agreements were identified through a comprehensive search of publicly available sources, including SEC filings (10-K, 10-Q, and 8-K filings), pharmaceutical industry databases (including the Vireo Health IT and Sundial Health IT databases), litigation disclosures, and published industry surveys. Each of the 14 agreements involves the licensing of pharmaceutical or biopharmaceutical intangible property between unrelated parties and satisfies the screening criteria described below.
Internal CUTs. C&H and Whitmore evaluated whether PPC maintains any third-party license agreements that could serve as internal CUTs — that is, licenses of the same or substantially similar legacy compounds to unrelated third parties. PPC's third-party licensing activity is limited. PPC has entered into certain distribution agreements with third-party distributors in specific country markets, but these arrangements are structured as distribution agreements with limited IP licensing components rather than as IP royalty licenses comparable to the Legacy License. Additionally, certain third-party license-back arrangements exist in connection with historical acquisition agreements, but these involve different compounds under different terms and are not directly comparable to the Legacy License. Accordingly, while PPC's internal licensing history was considered, the primary CUT data set consists of 14 external CUTs.
B. Comparability Analysis for the 14 CUT Agreements
Screening Criteria. Whitmore applied the following screening criteria to identify the 14 comparable uncontrolled pharmaceutical license agreements:
• Industry: The licensing agreements involve pharmaceutical or biopharmaceutical intangible property. Licenses involving medical devices, diagnostic tools, agricultural chemicals, or other non-pharmaceutical IP were excluded as insufficiently comparable to the Legacy License.
• Type of IP: The licensed IP consists of approved, commercialized pharmaceutical compounds — not early-stage R&D compounds, platform technology licenses, research tool licenses, or compound library access agreements. This criterion ensures that the comparables involve IP at a similar stage of commercial realization as PPC's legacy compounds.
• Rights conferred: The comparables involve exclusive territorial licenses, typically non-U.S. or specific regional grants (e.g., European Economic Area, Asia-Pacific, or defined multi-country regions). Non-exclusive licenses, worldwide licenses, and U.S.-only licenses were excluded or adjusted as appropriate.
• Stage of development: The comparables involve mature or post-launch compounds — products that have been commercially launched and are in the later stages of their commercial lifecycle. This criterion is critical to ensuring comparability with PPC's legacy compounds, which are in a declining phase. Agreements involving pre-launch or growth-stage compounds were excluded or subjected to comparability adjustments.
• Term: The comparables involve multi-year license agreements — not one-time lump-sum transfers, option agreements, or short-term research collaborations.
• Data availability: The comparable agreements are publicly available or disclosed in SEC filings, litigation records, or searchable databases, with sufficient detail regarding royalty rates, licensed products, territorial scope, and key terms to permit meaningful comparability analysis.
Comparability Adjustments Required and Made. No set of comparable uncontrolled transactions will perfectly match the controlled transaction in all respects. Accordingly, Whitmore identified the following categories of comparability differences and applied or will apply adjustments as appropriate:
Geographic Scope Adjustments. Some of the 14 comparable agreements cover different territory definitions than the non-Americas territory under the Legacy License. For example, certain comparables grant rights to a specific region (e.g., Europe only) while others grant broader non-U.S. rights. Adjustments were made to account for differences in territory size, market characteristics, and the number and diversity of country markets covered. In general, broader territorial grants covering more diverse markets with varying regulatory and pricing environments tend to be associated with moderately lower royalty rates, reflecting the greater operational complexity and risk borne by the licensee.
Product Lifecycle Adjustments. While the screening criteria targeted mature or post-launch compounds, certain comparables involve products at somewhat different stages of their lifecycle than PPC's legacy compounds. Products in the early post-launch or peak-sales phase generate higher expected revenues and therefore command higher royalty rates than products in the declining phase. Whitmore applied adjustments to normalize for lifecycle-stage differences, generally adjusting downward the royalty rates of comparables involving products with longer expected remaining commercial lives or more favorable competitive positions.
Exclusivity Adjustments. All 14 comparables involve exclusive territorial licenses, consistent with the Legacy License. However, the scope of exclusivity varies (e.g., sole and exclusive vs. exclusive with reserved rights). To the extent any comparables deviate from the exclusivity terms of the Legacy License, adjustments were considered.
Risk Allocation Adjustments. The allocation of risks between licensor and licensee varies across the comparable agreements. In some comparables, the licensee bears full market, regulatory, and pricing risk (consistent with the Legacy License), while in others, certain risks are shared with or retained by the licensor (e.g., through co-promotion arrangements, milestone-based pricing, or regulatory support obligations). Adjustments were made to account for these differences, recognizing that greater risk-bearing by the licensee supports a lower royalty rate.
Volume/Scale Adjustments. The legacy compounds generate significant annual net sales in the non-Americas territory ($624.1 million to $814.6 million during the examination period), which may differ from the sales volumes of the products covered by the comparable agreements. Volume-based adjustments were considered to the extent that royalty rates in the comparables were influenced by differences in sales scale.
Results. After application of the screening criteria and comparability adjustments, Whitmore's preliminary analysis of the 14 comparable uncontrolled pharmaceutical license agreements yields the following arm's-length range:
PPC's 4.5% royalty rate falls within the interquartile range (3.1% to 6.8%) and is essentially at the median of 4.4%. Under Treas. Reg. § 1.482-1(e), a controlled transaction that falls within the arm's-length range does not warrant an adjustment. PPC's royalty rate is not merely within the range — it is at the central tendency of the distribution. This provides PPC with a strong evidentiary position.
C. Specific Comparability Factors Favoring PPC's Rate
1. Declining Product Lifecycle. The most significant comparability factor favoring PPC's 4.5% royalty rate is the declining product lifecycle of the legacy compounds. Non-Americas net sales dropped from $814.6 million in 2017 to $624.1 million in 2020, a decline of approximately 23.4% over the four-year examination period. This decline trajectory is consistent with the natural lifecycle of branded pharmaceutical products facing loss of patent exclusivity, generic competition, and therapeutic displacement by newer agents.
The declining revenue trajectory directly reduces the present value of the IP to the licensee. From the licensee's perspective, the economic value of a license depends on the expected future cash flows attributable to the licensed IP. When those expected cash flows are declining — and when the licensee has no realistic expectation of revenue recovery absent significant new investment or reformulation — the license is inherently less valuable than a license of peak-stage or growth-stage IP. A rational arm's-length licensee in PBI's position would demand a lower royalty rate to reflect the diminishing value of the IP and the increasing risk that revenues will continue to decline. Conversely, a rational arm's-length licensor in PPC's position would accept a lower rate rather than risk the licensee declining to renew or maintain the license altogether.
Comparables involving blockbuster or high-growth pharmaceutical IP — where the expected revenue trajectory is upward and the product faces minimal near-term competitive threats — would significantly overstate the appropriate arm's-length royalty rate for PPC's declining legacy compounds. Any CUT analysis that fails to adjust for lifecycle-stage differences between the comparables and PPC's legacy compounds would produce unreliable results.
2. PBI's Substantive Functions and Risk-Bearing. A second critical factor favoring PPC's rate is PBI's status as a substantive, risk-bearing licensee — not a passive recipient of IP rights. The arm's-length standard recognizes that, in an uncontrolled transaction, a licensee that performs significant value-adding functions and bears substantial risks will negotiate a lower royalty rate than a licensee that merely distributes a finished product with minimal operational involvement.
PBI performs significant DEMPE functions — Development, Enhancement, Maintenance, Protection, and Exploitation — in connection with the commercialization of licensed products in the non-Americas territory:
• Development and Enhancement: While PPC owns the underlying IP, PBI contributes to the ongoing development and enhancement of the licensed products' commercial potential through label expansion submissions, formulation adaptations for local markets, and medical affairs-driven clinical evidence generation in non-Americas territories.
• Maintenance and Protection: PBI incurred €47.2 million cumulatively in regulatory expenditures during the examination period, maintaining regulatory approvals, managing pharmacovigilance obligations, and defending the intellectual property rights of the licensed products in the Licensed Territory.
• Exploitation: PBI independently develops and executes commercial strategy across 68 country markets, makes independent pricing decisions, manages key account relationships with healthcare systems and payers, and bears the full risk of commercial success or failure in each market.
PBI's economic substance is robust and well-documented. PBI maintained 185 employees as of December 31, 2020, occupying approximately 18,000 square feet of dedicated office space in Dublin. PBI's board of directors held 42 meetings during the 2017–2020 examination period — all in Dublin — reflecting active governance and independent decision-making. PBI managed its own treasury function through Glenmore Bank Ireland plc and engaged independent Irish tax advisors (Thornbury & Keogh) and auditors.
PBI's substantive functions and risk-bearing justify attributing a larger share of the profits from the Legacy License to PBI's own activities, and correspondingly a lower royalty rate to PPC's IP. An arm's-length royalty rate must reflect the relative contributions of both parties: PPC contributes the underlying IP (which is declining in value), and PBI contributes the operational infrastructure, market expertise, regulatory compliance, and risk-bearing necessary to exploit that IP across 68 diverse country markets. A 4.5% royalty rate appropriately reflects this allocation.
3. Exclusivity and Geographic Scope. The Legacy License grants PBI exclusive rights to commercialize the licensed compounds in the non-Americas territory. While exclusivity is a valuable right — and generally supports a higher royalty rate compared to a non-exclusive license — the geographic scope and market characteristics of the Licensed Territory introduce countervailing factors that moderate the value of the exclusivity grant.
The non-Americas territory encompasses a highly fragmented set of markets with significant regulatory, pricing, and reimbursement complexity. The territory includes markets with strict government price controls (e.g., France, Germany, Japan, South Korea), reference pricing systems that link prices across countries, mandatory rebate programs, and highly variable reimbursement processes. These market characteristics reduce the net value of the licensed IP to the licensee compared to, for example, a license for the U.S. market — where pricing is generally more favorable for branded pharmaceuticals and regulatory requirements, while stringent, are administered by a single agency (the FDA).
Additionally, the non-Americas territory requires the licensee to navigate approximately 68 distinct regulatory environments, each with its own marketing authorization requirements, post-marketing surveillance obligations, and pharmacovigilance standards. The operational burden and cost of maintaining compliance across these diverse jurisdictions are borne by PBI, not PPC, and represent a significant functional contribution that supports a lower royalty rate.
4. Absence of Sub-licensing Rights. Under the terms of the Legacy License, PBI does not have the right to sub-license the licensed IP to third parties without PPC's prior written consent. This restriction limits PBI's ability to exploit the licensed IP through third-party arrangements and reduces the flexibility and value of the license compared to a license that includes unrestricted sub-licensing rights. In the comparable uncontrolled transactions, licenses that include broader sub-licensing rights are generally associated with higher royalty rates, reflecting the greater flexibility

PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT

MEMORANDUM

Record

Parties

Dates

Amounts